KPV is a synthetic C-terminal tripeptide fragment of alpha-MSH studied in preclinical immunology research for its role in melanocortin receptor binding and NF-kB pathway modulation.
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). CAS: 13653-16-2. Unlike the full alpha-MSH peptide, KPV is studied for retaining anti-inflammatory activity while lacking the pigmentation-inducing effects associated with full-length melanocortin signaling, making it a compound of interest in preclinical immunomodulatory research distinct from pigmentation-focused melanocortin studies.
KPV has been studied for binding to melanocortin receptors, including MC1R and MC3R, expressed on immune cells such as macrophages and monocytes. Research has also proposed melanocortin-receptor-independent activity, including direct modulation of the NF-kB signaling pathway — a central regulator of pro-inflammatory gene transcription. This dual proposed mechanism has made KPV a reference compound in research examining inflammatory signaling pathways outside the classical melanocortin-pigmentation axis.
NuvoTide's KPV is supplied as a lyophilized powder, HPLC verified to ≥99% purity, and should be stored at -20°C prior to reconstitution. All NuvoTide Research products, including KPV, are supplied strictly for in-vitro laboratory research purposes and are not intended for human or veterinary use, and are not FDA-approved.
For in-vitro research use only. Not for human or veterinary use.